Intelligencia AI Awarded U.S. Patent for Its Accurate and Transparent Probability of Drug Success Assessments
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Intelligencia AI , a provider of AI-powered solutions that support data-driven decision-making in drug development, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No.
- NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Intelligencia AI , a provider of AI-powered solutions that support data-driven decision-making in drug development, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No.
- The patent includes the company’s flagship solution, Intelligencia Portfolio Optimizer , and its underlying methodology.
- The on-demand solution enables customers to objectively assess the probability of technical and regulatory success (PTRS) and phase transition probabilities.
- This patent has been a long time in the making and marks a significant milestone in signifying Intelligencia AI as a pioneer and a leader in applying AI to de-risk clinical development and enhance decision-making through accurate, AI-driven probability of success (PoS).”